Preventing Attacks Before They Happen
You are currently watching a preview of this interview. Unlock the full version by upgrading to an Access Pass bundle! Get FREE access to 8 expert interviews from Day 1 and Day 2 when you register today!
- When is preventive therapy for migraine recommended?
- Why is frequent use of acute migraine medications a problem?
- What are the major classes of medications for migraine prevention?
- How can an ineffective acute treatment lead to migraine chronification?
- What can we expect when our doctor puts us on preventive therapy?
- Why are migraine diaries important for migraine prevention?
- Are the CGRP medications effective in patients who haven’t responded to other therapies?
- What is polytherapy?
- When acute migraine medications don’t seem to be working, what can we do?
- Why would it be helpful for your provider to have your complete medical history, going back to childhood?
- Why are some patients labeled difficult to treat?
- Can adverse childhood experiences have an effect of migraine?
Jan Lewis Brandes, MD
Assistant Clinical Professor of Neurology
Jan Lewis Brandes, M.D., M.S., holds an appointment as an assistant clinical professor in the department of neurology at Vanderbilt University School of Medicine, Nashville, Tennessee; she is also the founding director of the Nashville Neuroscience Group, a private headache clinic in Nashville, Tennessee. Prior to attending Vanderbilt University School of Medicine, where she subsequently earned her medical degree, Dr. Brandes attended the Robert Koch Institute of Virology, Free University, in Berlin, Federal Republic of Germany, as a Fulbright Scholar. Her postgraduate medical training was completed at Vanderbilt University Medical Center, where she served as chief resident in neurology. She also holds an M.S. degree in microbiology from the University of Tennessee in Knoxville. She is certified by the National Board of Medical Examiners, the American Board of Psychiatry and Neurology, the National Board for Certification in Headache Management, and is UCNS-certified in headache medicine.
Dr. Brandes has been active in clinical trials for more than two decades. She has served as the principal or co-principal investigator in more than 100 studies, primarily examining issues in migraine including acute treatment, prophylaxis, and menstrual migraine. She has published extensively in peer-reviewed journals including JAMA, Cephalalgia, Headache, and Lancet Neurology.
Dr. Brandes is a fellow of the American Headache Society and the American Academy of Neurology. She is a former member of the board of directors of the American Headache Society, and is the past-president of the American Council for Headache Education. In recognition of her professional endeavors, she has been named to Best Doctors in America from 1996 to present.
Unlock all 32 expert interviews with your own copy of the 2022 Migraine World Summit. Includes:
- 32 expert interviews with seperate audio (MP3) files & transcripts
- 26 extended, uncut interview editions
- Lifetime access with no annual fee
Related Talks for: Day 3 (2021)
Over the past 50 years, our mission at the National Headache Foundation has been to further awareness of headache and migraine as legitimate neurobiological diseases. Much has changed during this time. With aid from advanced technology and clinical innovation, there are more treatment options than ever before. However, we understand that these diseases are still largely misunderstood and that finding the right treatment options for you requires insight.
Impel NeuroPharma, Inc. is a late-stage biopharmaceutical company focused on developing transformative therapies that unlock the full potential of therapeutic molecules for people living with CNS disorders with high unmet medical needs. Impel NeuroPharma is the first company to investigate targeting the upper nasal space with optimized therapeutic molecules and formulations for treating CNS diseases.